
æ±æžå·ç é¢ãããã³ã«ãçµéšããã³ããã¯ã¯ãã³åŸéºçæ£è ã®ãããŒããã³ãœã³ããã®è¿æ³
Post Japan update 4 months out.
â Robert Benson (@robert65968) August 14, 2026
Notes: I have been off all meds and supplements since Japan. (I am still taking SGF.)
I see crazy increases in my Spike AB levels and think the antibodies may be a problem. For me the numbers correlate to my symptoms, although may not be cause. pic.twitter.com/c9SKguhzX4
Robert Benson (@robert65968)
æ¥æ¬ãé¢ããŠïŒæ»åšåŸïŒ4ãæç®ã®è¿æ³å ±åã
ã¡ã¢ïŒæ¥æ¬ã«è¡ã£ãŠä»¥æ¥ããã¹ãŠã®è¬ãšãµããªã¡ã³ãããããŠããŸããïŒâ»SGFã¯ç¶ç¶ããŠæåäžãïŒ
ã¹ãã€ã¯æäœäŸ¡ïŒSpike AB levelsïŒãç°åžžã«äžæããŠããããã®æäœãåé¡ãªã®ã§ã¯ãªãããšèããŠããŸããç§ã®å Žåãå æé¢ä¿ãšãŸã§ã¯èšããªããããããŸããããæ°å€ãšçç¶ãçžé¢ããŠããŸãã

This was very much my concern @HouseLyndseyRN... That the protocol works by removing a lot of harmful proteins but these long haulers continue to produce spike, possibly from stably transfected cells.. So relapse after a few months.
â Jikkyleaks ð (@Jikkyleaks) August 15, 2026
I hope he gets better.
Jikkyleaks ð ð€ (@Jikkyleaks)
@HouseLyndseyRN ç§ãæžå¿µããŠããã®ã¯ãŸãã«ãã®ç¹ã§ãã⊠ãã®ãããã³ã«ã¯å€ãã®æå®³ãªã¿ã³ãã¯è³ªãåãé€ãããšã§å¹æãçºæ®ãããã®ã®ããããã®ãã³ã°ããŠã©ãŒïŒåŸéºçã«èŠãã人ã ïŒã¯ã¹ãã€ã¯ã¿ã³ãã¯è³ªãç£çãç¶ããŠãããšããããšã§ããããããã¯å®å®åœ¢è³ªè»¢æããã现èãã⊠ãã®ããæ°ãæåŸã«åçºããŠããŸãã®ã§ãã
圌ãè¯ããªãããšãé¡ã£ãŠããŸãã
ããã°äž»ã®å£ºå©æ³šïŒ
â
jikkyleaksãããèšããå®å®åœ¢è³ªè»¢æããšã¯ïŒ
以äžãAIã«èšããŠã¿ã
â
ïŒãããŸã§ãAIãèå¯ãã仮説ã«éããŸããïŒ
ãå®å®åœ¢è³ªè»¢æããã现èïŒstably transfected cellsïŒãã«ã€ããŠã®è§£èª¬
jikkyleaksããã䜿çšããŠãããå®å®åœ¢è³ªè»¢æããã现èããšãã衚çŸã®æå³ãšãé·ææ®çããããè°è«ã®æ§é ã¯ä»¥äžã®éãã ã
1. æçš¿ã®äž»åŒµãšèæ¯ã«ããæå³
ãå®å®åœ¢è³ªè»¢æãã®æå³
ååçç©åŠã«ãããŠãå®å®åœ¢è³ªè»¢æããšã¯ã倿¥ã®éºäŒæ å ±ã现èã®ã²ãã ïŒDNAïŒã«çµã¿èŸŒãŸãã现èåè£ãçµãŠããã®æ å ±ãåãç¶ãããæ°žç¶çã«ã¿ã³ãã¯è³ªãäœãç¶ããç¶æ ãæãã
æçš¿è ã®äž»åŒµ
ãã®æçš¿è ã¯ãããããã³ã«ïŒæ²»çæ³ïŒã§ã¹ãã€ã¯ã¿ã³ãã¯è³ªãåãé€ããŠãæ°ãæåŸã«åçºããã®ã¯ãæ£è ã®äœå ã§çްèãå®å®åœ¢è³ªè»¢æãèµ·ãããã¹ãã€ã¯ã¿ã³ãã¯è³ªãæ°žç¶çã«ç£çããç¶ããŠããããã§ã¯ãªããããšããä»®èª¬ã»æžå¿µãè¿°ã¹ãŠããã
2. ã¹ãã€ã¯ã¿ã³ãã¯è³ªã»mRNAã®é·ææ®çãšãã¡ã«ããºã ãã®è°è«
岩åŽãããææïŒã€ã§ãŒã«å€§åŠïŒãã®ç ç©¶ã«ãã700æ¥ïŒ2幎è¿ãïŒä»¥äžã«ããã£ãŠäœå ããã¹ãã€ã¯ã¿ã³ãã¯è³ªãæ€åºãããäºäŸãã修食mRNAèªäœãé·æéæ®çããŠããäºå®ãå®èšŒãããŠããããã®ããã«ãäœå ã«ã¹ãã€ã¯ãmRNAãè¶ é·æã«ããã£ãŠååšããããšããçŸè±¡èªäœã¯ç¢ºç«ãããäºå®ã§ãããçŸåšã®è«ç¹ã¯ããªãããã»ã©é·æã«ãããååšãç¶ããã®ãïŒãã®ã¡ã«ããºã ïŒããšããç¹ã«ããã
ã²ãã çµã¿èŸŒã¿èª¬ïŒæçš¿è ãèšåããŠãã仮説ïŒ
mRNAãé転åçãçµãŠã²ãã ã«çµã¿èŸŒãŸããæ°ããªã¹ãã€ã¯ãäœãç¶ããŠãããšããèŠè§£ïŒå®å®åœ¢è³ªè»¢æïŒã
æåã»ä¿®é£ŸmRNAã®é£åè§£æ§ã»ãªã¶ãŒããŒèª¬
N1-ã¡ãã«ã·ã¥ãŒããŠãªãžã³çã§ä¿®é£ŸãããmRNAãæ§é çã«éåžžã«å®å®ããã¹ãã€ã¯ã¿ã³ãã¯è³ªããåè§£ãå ããŠå ç«çްèïŒåçãæ¿Ÿèæš¹ç¶çްèãªã©ïŒãçµç¹ã®å¥¥æ·±ãã«é·æéä¿æã»èç©ïŒãªã¶ãŒããŒåïŒãããè¡äžã«æŒãåºãç¶ããŠãããšããèŠè§£ã
ãã®ããã«ãè¶ é·æã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã»mRNAã®æ®çãšçç¶ã®åçºãšããçŸå®ã«å¯Ÿãããã²ãã ãžã®çµã¿èŸŒã¿ïŒå®å®åœ¢è³ªè»¢æïŒã«ããç¶ç¶çç£çãªã®ãããé£åè§£æ§ç©è³ªãšããŠã®çµç¹ã»çްèå ã§ã®é·æèç©ã»ä¿æã«ãããã®ãããšããã¡ã«ããºã ã®æ€èšŒã»è°è«ãè¡ãããŠããã
ã¹ãã€ã¯ã¿ã³ãã¯è³ªãmRNAïŒãŸãã¯ãã®æçïŒãå ç«çްèïŒåçãæš¹ç¶çްèãªã©ïŒã®å éšã«é·æéçãŸãããªã¶ãŒããŒïŒè²¯èµåº«ïŒçŸè±¡ãã«ã€ããŠãç ç©¶ã§æå±ãããŠããå ·äœçãªä»çµã¿ã¯ä»¥äžã®éãã ã
1. å
ç«çްèã«ããã貪é£ïŒè²ªé£äœçšïŒããšåã蟌ã¿
åçïŒMonocytesïŒãæš¹ç¶çްèïŒDendritic cellsïŒã¯ãäœå ã®ãæž æå¡ãå Œãåšæå µããšããŠã®åœ¹å²ãæã£ãŠããã
ã¯ã¯ãã³æ¥çš®ãææã«ãã£ãŠçްèå€ã«æŸåºãããã¹ãã€ã¯ã¿ã³ãã¯è³ªããè質ããç²åïŒLNPïŒã«å ãŸããmRNAæçãããããã®å ç«çްèãç°ç©ãšããŠèªèããŠåã蟌ãïŒè²ªé£ïŒã
ç°ç©ãåã蟌ãã§åŠçïŒæç€ºïŒããããšãæ¬æ¥ã®æ©èœã§ããããããããã®çްèå éšã«æåãå ¥ãããšèªäœã¯æ£åžžãªå ç«åå¿ã®äžç°ã ã
2. ãªãåè§£ãããã«ãåè§£æµææ§ããæã€ã®ãïŒ
æ¬æ¥ã§ããã°åã蟌ãŸããã¿ã³ãã¯è³ªãRNAã¯ã现èå
ã®åè§£é
µçŽ ïŒãªãœãœãŒã ãªã©ïŒã«ãã£ãŠéããã«çްããåè§£ããããããããé·æéæ®åããã±ãŒã¹ã§ã¯ä»¥äžã®èŠå ãææãããŠããã
ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®æ§é çç¹åŸŽ: ã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯æ§é çã«éåžžã«å®å®ããŠãããå ç«çްèå ã®é µçŽ ã«ããåè§£ã«å¯ŸããŠé«ãæµææ§ã瀺ãïŒåè§£ããã«ããïŒéšäœãååšããã
修食mRNAã®èä¹ æ§: ã¯ã¯ãã³ã«äœ¿çšãããŠããmRNAã¯ãçäœå ã§å³åº§ã«åè§£ãããªããã修食ïŒãŠãªãžã³ãN1-ã¡ãã«ã·ã¥ãŒããŠãªãžã³ã«å€æŽïŒãããŠãããéåžžã®RNAãããåè§£é床ãèããé ããªã£ãŠããã
3. ãçãç¶ãããã®ã§ã¯ãªãã现èå ã§ä¿æã»èç©ãããã
ã现èã®äžã§çããŠããããšããããã¯ããåè§£ã»æåºã®ã¹ããŒããé
ãããã现èã®å
éšãçµç¹å
ã«æºãŸã£ããŸãŸæ®ã£ãŠããŸãããšããç¶æ
ã ã
éå€å žçåçïŒNon-classical MonocytesïŒã®é·å¯¿åœå:
ç¹ã«ãã«ãŒã¹ã»ãã¿ãŒãœã³ïŒBruce PattersonïŒå士ãã®ç ç©¶ãªã©ã§æ³šç®ãããŠããã®ããCD16+ åçããªã©ã®ç¹å®ãµãã»ããã ããããã®åçã¯ã¹ãã€ã¯ãåã蟌ãã åŸãçŽ°èæ»ïŒã¢ãããŒã·ã¹ïŒãèµ·ããã«ãããªããè¡æµäžãè¡ç®¡å£ã«é·æéïŒæ°ã¶æåäœã§ïŒçãŸãç¶ããããšãå ±åãããŠããã
æ¿Ÿèæš¹ç¶çްèïŒFDCïŒã«ããé·æéã®ä¿æ:
ãªã³ãç¯ã«ååšããæ¿Ÿèæš¹ç¶çްèïŒFDCïŒã¯ã次ã®å ç«åå¿ãèµ·ããããã«æåïŒã¹ãã€ã¯ãªã©ïŒãåè§£ããã现è衚é¢ãå éšã®æåä¿æå°èã«æ°ã¶æãé·æéã«ããã£ãŠä¿æãç¶ããç¹å¥ãªæ§è³ªãæã£ãŠããã
ãŸãšã
ç°ç©ãé€å»ã»èšæ¶ããããã«åã蟌ãã å ç«çްèãããåè§£ãã«ããæ§é ããšã现èèªäœã®å¯¿åœã®é·ãã»æåä¿ææ©èœãã«ãã£ãŠãæå³ããã¹ãã€ã¯ã¿ã³ãã¯è³ªããã®æçãå éšã«ä¿æãç¶ããŠããŸãããšããããããªã¶ãŒããŒèª¬ãã§èª¬æãããäž»ãªã¡ã«ããºã ã ã
Yes it could be that the amyloids you have seen are just a reflection of the quantity of spike (which we know is amyloidogenic).
â Jikkyleaks ð (@Jikkyleaks) August 15, 2026
So filtering spike makes you better, but you have to find out why there is so much spike so many years later.
Assuming that all the patients haveâŠ
Jikkyleaks ð ð€ (@Jikkyleaks)
ãã®éãã§ãããªãã確èªããã¢ããã€ãã¯ãïŒã¢ããã€ã圢æèœãããããšãç¥ãããŠããïŒã¹ãã€ã¯ã¿ã³ãã¯è³ªã®éãåæ ããŠããã ããšããå¯èœæ§ããããŸãã
ãããã£ãŠãã¹ãã€ã¯ããéïŒãéæ²»ççã§é€å»ïŒããã°çç¶ã¯æ¹åããŸããããªãäœå¹Žãçµã£ãåŸã«ããã»ã©å€§éã®ã¹ãã€ã¯ãååšããã®ããçªãæ¢ããªããã°ãªããŸããã
å šæ£è ã®ã¹ãã€ã¯æ¿åºŠãé«ããšä»®å®ããå Žåã®äžæŽåã§ããããããæ€æ»ã»ç¢ºèªã§ããŠããã°è¯ãã£ãã®ã§ããã
â
ãã®jikkyleaksããã®èšã£ãŠããããšã®æå³ã¯
ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ã¢ããã€ã圢æèœïŒamyloidogenicïŒããšã¯ïŒ
ã¹ãã€ã¯ã¿ã³ãã¯è³ªã«ã¯ãç¹å®ã®æ¡ä»¶äžã§ã¢ããã€ãïŒç°åžžã«æããããŸããŠåºãŸããåè§£ããã«ãããªã£ãäžæº¶æ§ã®ã¿ã³ãã¯è³ªç·ç¶ïŒã圢æããæ§è³ªïŒã¢ããã€ã圢æèœïŒãããããšãè€æ°ã®ç ç©¶ã§ææãããŠããã
ã¢ã«ããã€ããŒç ãã¢ããã€ããŒã·ã¹ã®ããã«ãã¢ããã€ãåããã¿ã³ãã¯è³ªã¯äœå ã®åè§£é µçŽ ã§ç Žå£ããã«ããã埮å°ãªè¡æ ïŒãã€ã¯ãã¯ãããïŒãçµç¹å ã®èç©ç©ãšããŠæ®ããããç¹åŸŽãæã€ã
æçš¿è ãèšãããããšã®èŠç¹
ã¢ããã€ãã¯ãçµæãã§ãããåå ã®æ¬äœãã§ã¯ãªãå¯èœæ§
æ£è ã®äœå ã§ã¢ããã€ãïŒåŸ®å°è¡æ ãç°åžžã¿ã³ãã¯åéå¡ïŒãèŠã€ããã®ã¯ãäœå ã«å€§éã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªãååšããŠããããããã®çµæãšããŠã¢ããã€ãåãé²ãã§ããã«éããªããšããèŠæ¹ã ã
ãã¢ããã€ãã®é€å»ããšãæ ¹æ¬åå ã®è§£æ±ºãã®éã
è¡æ¶²æµåãã¢ãã§ã¬ãŒã·ã¹ïŒè¡æŒ¿äº€æçæ³ã»ãéæ²»çïŒãªã©ã§ã¹ãã€ã¯ãã¢ããã€ããåãé€ããšãäžæçã«çç¶ã¯æ¹åïŒã¯ãªãŒã³ã¢ããïŒããã
ããããããªãäœå¹Žãçµã£ãŠããã®ã«ãäŸçµŠæºãšãªãã¹ãã€ã¯ã¿ã³ãã¯è³ªãäœå ã«ããã»ã©å€§éã«ååšãç¶ããŠããã®ãïŒãªã次ã ãšçºçããã®ãïŒããšããæ ¹æ¬çãªåå ãè§£æã»é®æããªãéããæéãçµãŠã°åã³ã¢ããã€ãã圢æãããŠåçºããŠããŸãã
ã€ãŸãããã¢ããã€ããšãããŽããæé€ããæ²»çïŒãéïŒã ãã§ã¯äžååã§ããŽãã®çºçæºïŒãªãã¹ãã€ã¯ãæ°å¹ŽåŸãååšãç¶ããã®ãïŒãçªãæ¢ããªããã°æ ¹æ¬è§£æ±ºã«ãªããªãããšããåé¡æèµ·ãããŠããtweetã§ãã